118 related articles for article (PubMed ID: 16401626)
1. Adverse neuropsychiatric effects of cytomegalovirus prophylaxis with valaciclovir in renal transplant recipients.
Das V; Peraldi MN; Legendre C
Nephrol Dial Transplant; 2006 May; 21(5):1395-401. PubMed ID: 16401626
[TBL] [Abstract][Full Text] [Related]
2. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
Abraham KA; O'Kelly P; Spencer S; Hickey DP; Conlon PJ; Walshe JJ
Ren Fail; 2008; 30(2):141-6. PubMed ID: 18300112
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience.
Sund F; Tufveson G; Döhler B; Opelz G; Eriksson BM
Nephrol Dial Transplant; 2013 Mar; 28(3):758-65. PubMed ID: 23243043
[TBL] [Abstract][Full Text] [Related]
4. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
[TBL] [Abstract][Full Text] [Related]
5. Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients.
Toussaint ND; Tan MB; Nicholls K; Walker RG; Cohney SJ
Nephrology (Carlton); 2011 Jan; 16(1):113-7. PubMed ID: 21175987
[TBL] [Abstract][Full Text] [Related]
6. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
Reddy SP; Handa A; Tan L; Devaney A; Hughes D; Mason P; Friend PJ; Darby CR
Transpl Int; 2003 Oct; 16(10):726-9. PubMed ID: 12827230
[TBL] [Abstract][Full Text] [Related]
7. Incidence and predictors of myocardial infarction after kidney transplantation.
Lentine KL; Brennan DC; Schnitzler MA
J Am Soc Nephrol; 2005 Feb; 16(2):496-506. PubMed ID: 15615820
[TBL] [Abstract][Full Text] [Related]
8. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus mismatch as major risk factor for delayed graft function after pancreas transplantation.
Maglione M; Biebl MO; Bonatti H; Göbel G; Ratschiller T; Schneeberger S; Brandacher G; Hengster P; Margreiter C; Berger N; Margreiter R; Pratschke J; Mark W
Transplantation; 2010 Sep; 90(6):666-71. PubMed ID: 20724959
[TBL] [Abstract][Full Text] [Related]
11. CMV disease in CMV-mismatched renal transplant recipients with prophylactic low dose valaciclovir.
Sund F; Wahlberg J; Eriksson BM
J Clin Virol; 2001 Dec; 23(1-2):107-11. PubMed ID: 11595589
[TBL] [Abstract][Full Text] [Related]
12. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
[TBL] [Abstract][Full Text] [Related]
13. A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation.
Tilden DP; Chapman J; Davey PJ; Solly ML; Crowley S
Clin Transplant; 2004 Jun; 18(3):312-20. PubMed ID: 15142054
[TBL] [Abstract][Full Text] [Related]
14. Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection.
Alain S; Hantz S; Scieux C; Karras A; Mazeron MC; Szelag JC; Imbert BM; Fillet AM; Gouarin S; Mengelle C; De Wilde A; Cogne N; Champier G; Rogez S; Legendre C; Denis F
J Med Virol; 2004 Aug; 73(4):566-73. PubMed ID: 15221901
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period.
Formica RN; Friedman AL; Lorber MI; Smith JD; Eisen T; Bia MJ
Nephrol Dial Transplant; 2006 May; 21(5):1389-94. PubMed ID: 16431893
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction.
Patel SJ; Duhart BT; Krauss AG; Moore LW; Egidi MF; Amiri HS; Gaber LW; Gaber AO
Transplantation; 2008 Jul; 86(2):313-20. PubMed ID: 18645496
[TBL] [Abstract][Full Text] [Related]
17. High-dose valaciclovir linked to problems.
TreatmentUpdate; 1998 Mar; 10(1):4-6. PubMed ID: 11365432
[TBL] [Abstract][Full Text] [Related]
18. Renal function and serum albumin at the start of dialysis in 514 Chinese ESRD in-patients.
Liu H; Peng Y; Liu F; Xiao H; Chen X; Huang A; Liu Y
Ren Fail; 2008; 30(7):685-90. PubMed ID: 18704816
[TBL] [Abstract][Full Text] [Related]
19. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for the development of delayed graft function in deceased donor renal transplants.
Jushinskis J; Trushkov S; Bicans J; Suhorukov V; Shevelev V; Ziedina I; Rozental R
Transplant Proc; 2009 Mar; 41(2):746-8. PubMed ID: 19328971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
